Sage国际出版集团
期刊
会议
图书
作者:Nicolas Simon , Pascal Odou , Bertrand Decaudin ...
来源:[J].Journal of Oncology Pharmacy Practice, 2019, Vol.25 (4), pp.929-946Sage国际出版集团
摘要:Although considerable efforts have been made over the last 40 years, occupational exposure to antineoplastic drugs is still a daily concern, since eradicating such contamination from workplaces seems unattainable. Considerable data are currently available on the risks associated ...
作者:Constantin A Dasanu
来源:[J].Journal of Oncology Pharmacy Practice, 2019, Vol.25 (4), pp.990-992Sage国际出版集团
摘要:Ruxolitinib is a small molecule JAK-2 inhibitor approved for the treatment of certain myeloproliferative neoplasms. Ruxolitinib-related skin toxicity is extremely rare. We report herein an unusual erythematous skin eruption with necrotic centers involving lower extremities in a p...
作者:Scott Edwards , Rick Abbott , George Dranitsaris
来源:[J].Journal of Oncology Pharmacy Practice, 2019, Vol.25 (4), pp.891-895Sage国际出版集团
摘要:Background(#br)There has been a dramatic increase in new drug approvals in oncology, consisting of both small molecule inhibitors and monoclonal antibodies. However, Health Canada approval for many of the new agents was based on single randomized trials consisting of only a ...
作者:Yanira Ruiz-Heredia , Beatriz Sanchez-Vega , Santiago Barrio ...
来源:[J].Journal of Oncology Pharmacy Practice, 2019, Vol.25 (4), pp.998-1002Sage国际出版集团
摘要:Progressive multifocal leukoencephalopathy rarely occurs in patients with multiple myeloma. Intracranial central nervous system invasion is also an uncommon event in multiple myeloma, occurring in less than 1% of cases. We describe herein an exceptional case of coexisting progres...
作者:Ali Alkan , Serap Talaz
来源:[J].Journal of Oncology Pharmacy Practice, 2019, Vol.25 (4), pp.969-971Sage国际出版集团
摘要:Introduction(#br)Cancer is an important risk factor for venous and arterial thromboembolic events. Treatment with chemotherapy was associated with a 6.5-fold increase in the risk of thromboembolic events. Here, we present a patient with cilioretinal artery emboli during cisplatin...
作者:Eiseki Usami , Michio Kimura , Mina Iwai ...
来源:[J].Journal of Oncology Pharmacy Practice, 2019, Vol.25 (4), pp.869-874Sage国际出版集团
摘要:Introduction(#br)Pegfilgrastim is a PEGylated formulation of filgrastim with a long half-life. It is highly convenient and less burdensome for patients. However, white blood cell count may temporarily increase after administration; in particular, a leukocyte overshoot may be...
作者:Darren Svirskis , Sairam Behera , Neera Naidoo ...
来源:[J].Journal of Oncology Pharmacy Practice, 2019, Vol.25 (4), pp.831-840Sage国际出版集团
摘要:Background(#br)The EPOCH regimen, consisting of vincristine sulfate, doxorubicin hydrochloride, and etoposide phosphate, is typically administered by continuous infusion over four days to oncology inpatients. If the EPOCH regimen was available to be administered through port...
作者:Maryanne Ong’udi , Pegotty Mutai , Irene Weru
来源:[J].Journal of Oncology Pharmacy Practice, 2019, Vol.25 (4), pp.918-928Sage国际出版集团
摘要:Introduction(#br)Cancer is not only a burden in the country but also a global burden with among the highest rate of mortality. In spite of the great strides made by the conventional therapy, many cancer patients have resorted to using complementary and alternative medicine (CAM) ...
作者:Diego Gutiérrez-Fernández , Mónica Saldaña-Valderas , Raquel de la Varga-Martínez ...
来源:[J].Journal of Oncology Pharmacy Practice, 2019, Vol.25 (4), pp.1016-1020Sage国际出版集团
摘要:We describe a successful desensitization to alemtuzumab in one patient diagnosed with T-cell prolymphocytic leukaemia. Alemtuzumab treatment was initiated during infusion number 18, the patient showed cutaneous eruption with a miliary pattern, despite premedication with corticost...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×